Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine 0.05% for Diabetic Dry Eye
NCT06824844Phase 4
Key facts
- Status
- Completed
- Start
- Dec 2021
- Primary completion
- Mar 2024
- Countries
- 1
- Sponsor
- Peking University Third Hospital
- Modality
- Peptides, Small Molecules
- Drugs
- cyclosporine
- Conditions
- dry eye disease (DED)
01
Overview
Phase 4, randomised trial of cyclosporine in dry eye disease (DED) (2 arms), sponsored by Peking University Third Hospital. Primary endpoints: Ocular Surface Disease Index at 3 months, Tear Break-up Time at 3 months and 3 more. Started Dec 2021; status: completed.
02
Design
2 arms- Study design
- Randomized
Cyclosporine + Artificial Tears
0.05% cyclosporine eyedrops (bid) + artificial tear eyedrops (qid)
Artificial Tears
Artificial tear eyedrops (qid)
03
Who it enrols
Diabetic patients (Type 2, >= 5 years) aged 50-70 with diagnosed dry eye disease, excluding those with active ocular infection/inflammation, severe blepharitis, or corneal nerve diseases.
04
Endpoints
Primary
Ocular Surface Disease Index
Tear Break-up Time
Corneal Fluorescein Staining
Schirmer I Test
Lissamine Green Staining
Secondary
Corneal Sensitivity
Interleukin-1beta Concentration
Interleukin-6 Concentration
Interleukin-10 Concentration
Interleukin-17A Concentration
Beyond the preview
Go deeper on NCT06824844.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06824844.